Here’s what you need to know about BioAge’s IPO. BioAge Labs, Inc. is a clinical-stage biopharmaceutical firm based in ...

More on BioAge Labs, Inc. BioAge Labs Readies $100 Million IPO Plan For Obesity Treatment Weight-loss drug developer BioAge ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive ...

BioAge CEO and co-founder Kristen Fortney would own 6.7% of the company after the IPO. The offering would be the first Bay Area biotech IPO since February and only the fourth this year.

At the closing bell, BioAge’s stock BIOA stood at $18.31 for a 1.7% gain over its IPO price. Earlier, the stock had been up as much as 30%.

BioAge just completed its IPO to continue funding clinical trials, but competition will be stiff. BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.

In that vein, there's a biotech stock called BioAge Labs (NASDAQ: BIOA) that just wrapped up its initial public offering (IPO) and is aiming to compete in the same areas as Lilly, as well as one ...

BioAge priced its offering of 11 million shares at $18 each, within its marketed range of $17 and $19 apiece. The IPO valued the Richmond, California-based company at $606 million. Meanwhile ...

BioAge Labs raised $238.3 million in its IPO. Moreover, the company's S-1 Filing shows that operating expenses were $28.1 million through the first six months of 2024 -- implying an annual run ...